SUNSHINE BIOPHARMA BELIEVES THAT AN EFFECTIVE CORONAVIRUS TREATMENT CONTINUES TO BE NECESSARY
November 24 2020 - 8:00AM
InvestorsHub NewsWire
SUNSHINE
BIOPHARMA BELIEVES THAT
AN EFFECTIVE CORONAVIRUS
TREATMENT
CONTINUES TO
BE NECESSARY
Montreal, Canada -- November
24, 2020 -- InvestorsHub NewsWire -- Sunshine Biopharma Inc.
(OTC
Pink:
"SBFM"), a pharmaceutical company focused on the research,
development and commercialization of oncology and antiviral
drugs today
announced that it is pushing ahead with its
Anti-Coronavirus drug development
program. While the recent announcements about effective vaccines
on the
horizon is a
cause for celebration, Sunshine Biopharma
believes that a treatment
for Coronavirus
infections continues to be essential for any robust healthcare system. This
is particularly
important
in view of the fact
that gaps
and lapses will likely occur during vaccine implementation
and people
may fall ill and require treatment. In addition, a treatment that
can be taken orally at home, much like an antibiotic, would be an
ideal complement for vaccination.
"SARS-CoV-2, the causative agent
of COVID-19, is the third in a line of Betacoronaviruses
that have caused serious human health threats in the past. The
first two were SARS-CoV that appeared
in 2002
and MERS-CoV in 2015," said Dr. Steve N.
Slilaty, CEO of Sunshine Biopharma. "There is nothing that says
that another Betacoronavirus with a potential for causing yet
another serious threat to human health won't
appear in the future. It is critical for us to have a
treatment for today and
as part of our
preparedness for the
future," he
added.
About
Sunshine Biopharma's Coronavirus Treatment
Severe Acute Respiratory
Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of
COVID-19, the current ongoing pandemic that has claimed the lives
of over 1.3
million people worldwide since it first
appeared in December 2019. There are currently no drugs that can
effectively arrest replication of the virus in people who have
contracted the illness. On May 22, 2020, Sunshine Biopharma filed a
provisional patent application for a library of molecules which
were designed to inhibit the Coronavirus proteases, thus shutting
down the ability of the virus to multiply and cause illness.
Sunshine Biopharma
has since screened the library and identified a lead
Anti-Coronavirus compound (SBFM-PL4). The Company is currently
conducting a
series of in
vitro tests to
evaluate its specific inhibitory activity of SBFM-PL4 against the SARS-CoV-2
papain-like protease (PLpro), one of two Coronavirus encoded
proteases essential for viral replication. Following the
initial in
vitro studies,
SBFM-PL4 will be moved forward to the cell culture testing stage
and assessment in Coronavirus infected mice before entering human
clinical trials.
About
Sunshine Biopharma
In addition,
to working on the
development of a treatment for COVID-19, Sunshine Biopharma is engaged in the
development Adva-27a, a unique anticancer compound. Tests
conducted to
date have
demonstrated the effectiveness of Adva-27a at destroying Multidrug
Resistant Cancer Cells, including Pancreatic Cancer
cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and
Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer
indication are planned to be conducted at McGill University's
Jewish General Hospital in Montreal, Canada. Sunshine
Biopharma is owner of all patents and intellectual property
pertaining to Adva-27a.
Safe Harbor
Forward-Looking Statements
This
press release may contain forward looking statements which are
based on current expectations, forecasts, and assumptions that
involve risks as well as uncertainties that could cause actual
outcomes and results to differ materially from those anticipated or
expected, including statements related to the amount and timing of
expected revenues statements related to our financial performance,
expected income, distributions, and future growth for upcoming
quarterly and annual periods. These risks and uncertainties are
further defined in filings and reports by the Company with the U.S.
Securities and Exchange Commission (SEC).
Actual
results and the timing of certain events could differ materially
from those projected in or contemplated by the forward-looking
statements due to a number of factors detailed from time to time in
our filings with the SEC. Among other matters, the Company may not
be able to sustain growth or achieve profitability based upon many
factors including but not limited to general stock market
conditions. Reference is hereby made to cautionary statements set
forth in the Company's most recent SEC filings. We have incurred
and will continue to incur significant expenses in our expansion of
our existing as well as new service lines noting there is no
assurance that we will generate enough revenues to offset those
costs in both the near and long term.
Additional
service offerings may expose us to additional legal and regulatory
costs and unknown exposure(s) based upon the various geopolitical
locations we will be providing services in, the impact of which
cannot be predicted at this time.
For
Additional Information:
Sunshine
Biopharma, Inc.
Camille Sebaaly, CFO
Direct Line:
514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com